An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma
Author:
Publisher
Elsevier BV
Subject
Dermatology
Reference20 articles.
1. Basal cell carcinomas: attack of the hedgehog;Epstein;Nat Rev Cancer,2008
2. Efficacy and safety of vismodegib in advanced basal-cell carcinoma;Sekulic;N Engl J Med,2012
3. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome;Tang;N Engl J Med,2012
4. Nonmelanoma skin cancer in the United States: incidence;Miller;J Am Acad Dermatol,1994
5. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011;Wysong;JAMA Dermatol,2013
Cited by 120 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Role of targeted therapy in ophthalmic tumors;Indian Journal of Clinical and Experimental Ophthalmology;2024-07-15
2. Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma;Dermatology Reports;2024-07-03
3. Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma;Journal of Clinical Oncology;2024-07-01
4. Oral Hedgehog Inhibitor, Vismodegib, for Locally Advanced Periorbital and Orbital Basal Cell Carcinoma;Ophthalmology;2024-07
5. Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies;American Journal of Clinical Dermatology;2024-06-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3